Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.

Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram DE, Severson E, Hemmerich A, Edgerly C, Duncan D, Britt N, Huang RSP, Elvin J, Miller V, Ross JS, Gay L, McCorkle J, Rankin A, Erlich RL, Chudnovsky Y, Ramkissoon SH.

Oncologist. 2020 Feb;25(2):e198-e202. doi: 10.1634/theoncologist.2019-0603. Epub 2019 Oct 16.

2.

Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib.

Hassan M, Butler E, Wilson R, Roy A, Zheng Y, Liem P, Rakheja D, Pavlick D, Young LL, Rosenzweig M, Erlich R, Ali SM, Leavey PJ, Parsons DW, Skapek SX, Laetsch TW.

Cold Spring Harb Mol Case Stud. 2019 Oct 23;5(5). pii: a004440. doi: 10.1101/mcs.a004440. Print 2019 Oct.

3.

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.

Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram DE, Severson E, Hemmerich A, Edgerly C, Duncan D, Britt N, Huang RSP, Elvin J, Miller V, Ross JS, Gay L, McCorkle J, Rankin A, Erlich RL, Chudnovsky Y, Ramkissoon SH.

Oncologist. 2019 Oct 16. pii: theoncologist.2019-0603. doi: 10.1634/theoncologist.2019-0603. [Epub ahead of print] Review.

4.

MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation.

Chu LP, Franck D, Parachoniak CA, Gregg JP, Moore MG, Farwell DG, Rao S, Heilmann AM, Erlich RL, Ross JS, Miller VA, Ali S, Riess JW.

Oncologist. 2019 Oct;24(10):1305-1308. doi: 10.1634/theoncologist.2019-0230. Epub 2019 Aug 7.

5.

SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association.

Lin DI, Allen JM, Hecht JL, Killian JK, Ngo NT, Edgerly C, Severson EA, Ali SM, Erlich RL, Ramkissoon SH, Vergilio JA, Ross JS, Elvin JA.

Mod Pathol. 2019 Nov;32(11):1675-1687. doi: 10.1038/s41379-019-0303-z. Epub 2019 Jun 12.

PMID:
31190001
6.

Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.

Reitsma M, Fox J, Borre PV, Cavanaugh M, Chudnovsky Y, Erlich RL, Gribbin TE, Anhorn R.

J Manag Care Spec Pharm. 2019 May;25(5):601-611. doi: 10.18553/jmcp.2019.18309. Epub 2019 Jan 11.

7.

Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling.

Tarlock K, Zhong S, He Y, Ries R, Severson E, Bailey M, Morley S, Balasubramanian S, Erlich R, Lipson D, Otto GA, Vergillo JA, Kolb EA, Ross JS, Mughal T, Stephens PJ, Miller V, Meshinchi S, He J.

Oncotarget. 2018 May 29;9(41):26417-26430. doi: 10.18632/oncotarget.25443. eCollection 2018 May 29.

8.

BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.

Gornstein EL, Sandefur S, Chung JH, Gay LM, Holmes O, Erlich RL, Soman S, Martin LK, Rose AV, Stephens PJ, Ross JS, Miller VA, Ali SM, Blau S.

Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21. No abstract available.

PMID:
29325860
9.

Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.

Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, Daniel S, Covert M, Frampton GM, Hsu S, Lesser GJ, Stogner-Underwood K, Mott RT, Rush SZ, Stanke JJ, Dahiya S, Sun J, Reddy P, Chalmers ZR, Erlich R, Chudnovsky Y, Fabrizio D, Schrock AB, Ali S, Miller V, Stephens PJ, Ross J, Crawford JR, Ramkissoon SH.

Oncologist. 2017 Dec;22(12):1478-1490. doi: 10.1634/theoncologist.2017-0242. Epub 2017 Sep 14.

10.

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib.

Oztan A, Fischer S, Schrock AB, Erlich RL, Lovly CM, Stephens PJ, Ross JS, Miller V, Ali SM, Ou SI, Raez LE.

Lung Cancer. 2017 Sep;111:84-87. doi: 10.1016/j.lungcan.2017.07.002. Epub 2017 Jul 8.

PMID:
28838405
11.

Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia.

Heilmann AM, Schrock AB, He J, Nahas M, Curran K, Shukla N, Cramer S, Draper L, Verma A, Erlich R, Ross J, Stephens P, Miller VA, Ali SM, Verglio JA, Tallman MS, Mughal TI.

Leukemia. 2017 Sep;31(9):1989-1992. doi: 10.1038/leu.2017.161. Epub 2017 May 29. No abstract available.

PMID:
28552906
12.

Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant.

Parachoniak CA, Rankin A, Gaffney B, Hartmaier R, Spritz D, Erlich RL, Miller VA, Morosini D, Stephens P, Ross JS, Keech J Jr, Chmielecki J.

Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5). pii: a000778. doi: 10.1101/mcs.a000778. Print 2017 Sep.

13.

Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA.

Lai AZ, Schrock AB, Erlich RL, Ross JS, Miller VA, Yakirevich E, Ali SM, Braiteh F.

Oncologist. 2017 Jul;22(7):774-779. doi: 10.1634/theoncologist.2016-0376. Epub 2017 May 15.

14.

Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.

Vanden Borre P, Schrock AB, Anderson PM, Morris JC 3rd, Heilmann AM, Holmes O, Wang K, Johnson A, Waguespack SG, Ou SI, Khan S, Fung KM, Stephens PJ, Erlich RL, Miller VA, Ross JS, Ali SM.

Oncologist. 2017 Mar;22(3):255-263. doi: 10.1634/theoncologist.2016-0279. Epub 2017 Feb 16.

15.

Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.

Allen JM, Schrock AB, Erlich RL, Miller VA, Stephens PJ, Ross JS, Ou SI, Ali SM, Vafai D.

Clin Lung Cancer. 2017 May;18(3):e219-e222. doi: 10.1016/j.cllc.2016.12.006. Epub 2016 Dec 22. No abstract available.

16.

Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra.

Chmielecki J, Bailey M, He J, Elvin J, Vergilio JA, Ramkissoon S, Suh J, Frampton GM, Sun JX, Morley S, Spritz D, Ali S, Gay L, Erlich RL, Ross JS, Buxhaku J, Davies H, Faso V, Germain A, Glanville B, Miller VA, Stephens PJ, Janeway KA, Maris JM, Meshinchi S, Pugh TJ, Shern JF, Lipson D.

Cancer Res. 2017 Jan 15;77(2):509-519. doi: 10.1158/0008-5472.CAN-16-1106. Epub 2017 Jan 9.

17.

TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies.

Lara PN Jr, Heilmann AM, Elvin JA, Parikh M, de Vere White R, Gandour-Edwards R, Evans CP, Pan CX, Schrock AB, Erlich R, Ross JS, Stephens PJ, McPherson J, Miller VA, Ali SM.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00065. Epub 2017 Nov 2.

18.

A case of advanced infantile myofibromatosis harboring a novel MYH10-RET fusion.

Rosenzweig M, Ali SM, Wong V, Schrock AB, Laetsch TW, Ahrens W, Heilmann A, Morley S, Chudnovsky Y, Erlich RL, Wang K, Stephens PJ, Ross JS, Miller VA, Oesterheld J.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26377. Epub 2016 Dec 28. No abstract available.

PMID:
28028925
19.

Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.

Thorpe LM, Schrock AB, Erlich RL, Miller VA, Knost J, Le-Lindqwister N, Jujjavarapu S, Ali SM, Liu JJ.

Head Neck. 2017 Mar;39(3):E40-E44. doi: 10.1002/hed.24634. Epub 2016 Dec 22. Review.

PMID:
28006087
20.

Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.

Subbiah V, Holmes O, Gowen K, Spritz D, Amini B, Wang WL, Schrock AB, Meric-Bernstam F, Zinner R, Piha-Paul S, Zarzour M, Elvin JA, Erlich RL, Stockman DL, Vergilio JA, Suh JH, Stephens PJ, Miller V, Ross JS, Ali SM.

Oncology. 2016;91(6):348-353. Epub 2016 Oct 21.

21.

Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.

Rankin A, Klempner SJ, Erlich R, Sun JX, Grothey A, Fakih M, George TJ Jr, Lee J, Ross JS, Stephens PJ, Miller VA, Ali SM, Schrock AB.

Oncologist. 2016 Nov;21(11):1306-1314. doi: 10.1634/theoncologist.2016-0148. Epub 2016 Sep 28.

22.

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.

Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, Halmos B, Goldman J, Forde P, Leuenberger K, Peled N, Kalemkerian GP, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH.

J Thorac Oncol. 2016 Sep;11(9):1493-502. doi: 10.1016/j.jtho.2016.06.004. Epub 2016 Jun 22.

23.

Unique genomic features in adolescent and young adult, as compared to older adult, non-Hodgkin lymphoma and potential therapeutic targets.

Johnson A, Morosini D, Vergilio JA, Yelensky R, Rosenzweig M, Khaira D, Ali SM, Palma N, Lipson D, Juhn F, Erlich R, Stephens PJ, Ross JS, Miller VA, Wang K.

Br J Haematol. 2017 Aug;178(4):640-642. doi: 10.1111/bjh.14157. Epub 2016 Jun 12. No abstract available.

PMID:
27291498
24.

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

Heilmann AM, Subbiah V, Wang K, Sun JX, Elvin JA, Chmielecki J, Sherman SI, Murthy R, Busaidy NL, Subbiah I, Yelensky R, Nangia C, Vergilio JA, Khan SA, Erlich RL, Lipson D, Ross JS, Miller VA, Shah MH, Ali SM, Stephens PJ.

Oncology. 2016;90(6):339-46. doi: 10.1159/000445978. Epub 2016 May 21.

25.

Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes.

Chung JH, Sanford E, Johnson A, Klempner SJ, Schrock AB, Palma NA, Erlich RL, Frampton GM, Chalmers ZR, Vergilio J, Rubinson DA, Sun JX, Chmielecki J, Yelensky R, Suh JH, Lipson D, George TJ Jr, Elvin JA, Stephens PJ, Miller VA, Ross JS, Ali SM.

Ann Oncol. 2016 Jul;27(7):1336-41. doi: 10.1093/annonc/mdw152. Epub 2016 Apr 6.

26.

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.

He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, Patel J, Krivstov A, Frampton GM, Young LE, Zhong S, Bailey M, White JR, Roels S, Deffenbaugh J, Fichtenholtz A, Brennan T, Rosenzweig M, Pelak K, Knapp KM, Brennan KW, Donahue AL, Young G, Garcia L, Beckstrom ST, Zhao M, White E, Banning V, Buell J, Iwanik K, Ross JS, Morosini D, Younes A, Hanash AM, Paietta E, Roberts K, Mullighan C, Dogan A, Armstrong SA, Mughal T, Vergilio JA, Labrecque E, Erlich R, Vietz C, Yelensky R, Stephens PJ, Miller VA, van den Brink MR, Otto GA, Lipson D, Levine RL.

Blood. 2016 Jun 16;127(24):3004-14. doi: 10.1182/blood-2015-08-664649. Epub 2016 Mar 10.

27.

Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing.

Schrock AB, Frampton GM, Herndon D, Greenbowe JR, Wang K, Lipson D, Yelensky R, Chalmers ZR, Chmielecki J, Elvin JA, Wollner M, Dvir A, -Gutman LS, Bordoni R, Peled N, Braiteh F, Raez L, Erlich R, Ou SH, Mohamed M, Ross JS, Stephens PJ, Ali SM, Miller VA.

Clin Cancer Res. 2016 Jul 1;22(13):3281-5. doi: 10.1158/1078-0432.CCR-15-1668. Epub 2016 Mar 1.

28.

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.

Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, Palmer G, Yelensky R, Lipson DM, Chmielecki J, Erlich RL, Rankin AN, Ali SM, Elvin JA, Morosini D, Miller VA, Stephens PJ.

JAMA Oncol. 2015 Apr;1(1):40-49. doi: 10.1001/jamaoncol.2014.216. Erratum in: JAMA Oncol. 2019 Aug 1;5(8):1232.

PMID:
26182302
29.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA.

Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13.

30.

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

Ali SM, Sanford EM, Klempner SJ, Rubinson DA, Wang K, Palma NA, Chmielecki J, Yelensky R, Palmer GA, Morosini D, Lipson D, Catenacci DV, Braiteh F, Erlich R, Stephens PJ, Ross JS, Ou SH, Miller VA.

Oncologist. 2015 May;20(5):499-507. doi: 10.1634/theoncologist.2014-0378. Epub 2015 Apr 16.

31.

Correction to "effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers".

Boyer C, Teo J, Phillips P, Erlich RB, Sagnella S, Sharbeen G, Dwarte T, Duong HT, Goldstein D, Davis TP, Kavallaris M, McCarroll J.

Mol Pharm. 2015 Mar 2;12(3):1004. doi: 10.1021/acs.molpharmaceut.5b00092. Epub 2015 Feb 18. No abstract available.

PMID:
25693032
32.

Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.

Chalmers ZR, Ali SM, Ohgami RS, Campregher PV, Frampton GM, Yelensky R, Elvin JA, Palma NA, Erlich R, Vergilio JA, Chmielecki J, Ross JS, Stephens PJ, Hermann R, Miller VA, Miles CR.

Blood Cancer J. 2015 Feb 6;5:e278. doi: 10.1038/bcj.2014.95. No abstract available.

33.

Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.

McCarroll JA, Dwarte T, Baigude H, Dang J, Yang L, Erlich RB, Kimpton K, Teo J, Sagnella SM, Akerfeldt MC, Liu J, Phillips PA, Rana TM, Kavallaris M.

Oncotarget. 2015 May 20;6(14):12020-34.

34.

TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer.

McCarroll JA, Gan PP, Erlich RB, Liu M, Dwarte T, Sagnella SS, Akerfeldt MC, Yang L, Parker AL, Chang MH, Shum MS, Byrne FL, Kavallaris M.

Cancer Res. 2015 Jan 15;75(2):415-25. doi: 10.1158/0008-5472.CAN-14-2740. Epub 2014 Nov 20.

35.

A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib.

Chung JH, Ali SM, Davis J, Robstad K, McNally R, Gay LM, Erlich RL, Palma NA, Stephens PJ, Miller VA, Cutugno A, Ross JS.

Case Rep Oncol. 2014 Sep 9;7(3):628-32. doi: 10.1159/000367780. eCollection 2014 Sep.

36.

Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial.

Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB.

Cancer Immunol Res. 2014 Aug;2(8):720-4. doi: 10.1158/2326-6066.CIR-14-0024. Epub 2014 May 6.

37.

A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.

Ross JS, Wang K, Gay LM, Al-Rohil RN, Nazeer T, Sheehan CE, Jennings TA, Otto GA, Donahue A, He J, Palmer G, Ali S, Nahas M, Young G, Labrecque E, Frampton G, Erlich R, Curran JA, Brennan K, Downing SR, Yelensky R, Lipson D, Hawryluk M, Miller VA, Stephens PJ.

Clin Cancer Res. 2014 Jan 1;20(1):68-75. doi: 10.1158/1078-0432.CCR-13-1992. Epub 2013 Nov 5.

38.

Using fluorescence lifetime imaging microscopy to monitor theranostic nanoparticle uptake and intracellular doxorubicin release.

Basuki JS, Duong HT, Macmillan A, Erlich RB, Esser L, Akerfeldt MC, Whan RM, Kavallaris M, Boyer C, Davis TP.

ACS Nano. 2013 Nov 26;7(11):10175-89. doi: 10.1021/nn404407g. Epub 2013 Oct 16.

PMID:
24131276
39.

Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers.

Boyer C, Teo J, Phillips P, Erlich RB, Sagnella S, Sharbeen G, Dwarte T, Duong HT, Goldstein D, Davis TP, Kavallaris M, McCarroll J.

Mol Pharm. 2013 Jun 3;10(6):2435-44. doi: 10.1021/mp400049e. Epub 2013 May 6. Erratum in: Mol Pharm. 2015 Mar 2;12(3):1004.

PMID:
23611705
40.

Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia.

Lane AA, Odejide O, Kopp N, Kim S, Yoda A, Erlich R, Wagle N, Abel GA, Rodig SJ, Antin JH, Weinstock DM.

Leukemia. 2013 Apr;27(4):968-71. doi: 10.1038/leu.2013.30. Epub 2013 Feb 1. No abstract available.

41.

Intracellular nitric oxide delivery from stable NO-polymeric nanoparticle carriers.

Duong HT, Kamarudin ZM, Erlich RB, Li Y, Jones MW, Kavallaris M, Boyer C, Davis TP.

Chem Commun (Camb). 2013 May 14;49(39):4190-2. doi: 10.1039/c2cc37181b. Epub 2012 Nov 16.

PMID:
23160081
42.

Cooking as a healthy behaviour.

Erlich R, Yngve A, Wahlqvist ML.

Public Health Nutr. 2012 Jul;15(7):1139-40. doi: 10.1017/S1368980012002662. No abstract available.

PMID:
23062443
43.

Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.

Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, Carneiro MO, Carter SL, Cibulskis K, Erlich RL, Greulich H, Lawrence MS, Lennon NJ, McKenna A, Meldrim J, Ramos AH, Ross MG, Russ C, Shefler E, Sivachenko A, Sogoloff B, Stojanov P, Tamayo P, Mesirov JP, Amani V, Teider N, Sengupta S, Francois JP, Northcott PA, Taylor MD, Yu F, Crabtree GR, Kautzman AG, Gabriel SB, Getz G, Jäger N, Jones DT, Lichter P, Pfister SM, Roberts TM, Meyerson M, Pomeroy SL, Cho YJ.

Nature. 2012 Aug 2;488(7409):106-10. doi: 10.1038/nature11329.

44.

Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans.

McLaren PJ, Ripke S, Pelak K, Weintrob AC, Patsopoulos NA, Jia X, Erlich RL, Lennon NJ, Kadie CM, Heckerman D, Gupta N, Haas DW, Deeks SG, Pereyra F, Walker BD, de Bakker PI; International HIV Controllers Study.

Hum Mol Genet. 2012 Oct 1;21(19):4334-47. doi: 10.1093/hmg/dds226. Epub 2012 Jun 19.

45.

Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection.

Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, Berlin AM, Malboeuf CM, Ryan EM, Gnerre S, Zody MC, Erlich RL, Green LM, Berical A, Wang Y, Casali M, Streeck H, Bloom AK, Dudek T, Tully D, Newman R, Axten KL, Gladden AD, Battis L, Kemper M, Zeng Q, Shea TP, Gujja S, Zedlack C, Gasser O, Brander C, Hess C, Günthard HF, Brumme ZL, Brumme CJ, Bazner S, Rychert J, Tinsley JP, Mayer KH, Rosenberg E, Pereyra F, Levin JZ, Young SK, Jessen H, Altfeld M, Birren BW, Walker BD, Allen TM.

PLoS Pathog. 2012;8(3):e1002529. doi: 10.1371/journal.ppat.1002529. Epub 2012 Mar 8.

46.

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.

Erlich RB, Kherrouche Z, Rickwood D, Endo-Munoz L, Cameron S, Dahler A, Hazar-Rethinam M, de Long LM, Wooley K, Guminski A, Saunders NA.

Br J Cancer. 2012 Jan 3;106(1):107-15. doi: 10.1038/bjc.2011.495. Epub 2011 Nov 24.

47.

Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors.

Miljković MD, Girotra M, Abraham RR, Erlich RB.

Dig Dis Sci. 2012 Jan;57(1):9-18. doi: 10.1007/s10620-011-1854-0. Epub 2011 Sep 22. Review.

PMID:
21938486
48.

Direct cardiac invasion of hepatocellular carcinoma with ball-valve phenomenon.

Kanda BS, Girotra M, Bailon O, Kant R, Dubin J, Erlich RB.

Am Surg. 2011 Apr;77(4):512-4. No abstract available.

PMID:
21679574
49.

Next-generation sequencing for HLA typing of class I loci.

Erlich RL, Jia X, Anderson S, Banks E, Gao X, Carrington M, Gupta N, DePristo MA, Henn MR, Lennon NJ, de Bakker PI.

BMC Genomics. 2011 Jan 18;12:42. doi: 10.1186/1471-2164-12-42.

50.

Analysis of pluripotent stem cells by using cryosections of embryoid bodies.

Gomes IC, Acquarone M, Maciel Rde M, Erlich RB, Rehen SK.

J Vis Exp. 2010 Dec 8;(46). pii: 2344. doi: 10.3791/2344.

Supplemental Content

Loading ...
Support Center